United States Patent 8,173,107: Loxapine Inhalation Aerosol Claims and Patent Landscape

US Patent 8,173,107 protects a loxapine inhalation aerosol defined by particle engineering rather than by a particular indication, dose, inhaler, or treatment method. Its independent claims require condensation particles, an aerodynamic particle-size range, and a high particle concentration or particle density. The patent is commercially relevant to Adasuve, the FDA-approved inhaled loxapine product.

The strongest infringement theory would require proof that a competing product contains loxapine condensation particles with an MMAD between 0.2 and 5 microns and a concentration exceeding the claimed threshold. The patent does not broadly cover every inhaled loxapine formulation. It is materially narrower than a claim directed to loxapine inhalation generally.

What does US Patent 8,173,107 cover?

US 8,173,107 covers an aerosol for delivering loxapine by inhalation. The claims focus on four technical limitations:

Claim element	Requirement
Active ingredient	Loxapine
Particle type	Condensation particles
Aerodynamic size	MMAD of 0.2 to 5 microns in claims 1 and 5
Concentration	“High particle concentration” in claim 1, or density greater than 10^6 particles/ml in claim 5
Optional narrowing feature	At least 90% free of additional compounds
Preferred size	MMAD of 1 to 3 microns
Preferred density	About 10^9 particles/ml

The patent is assigned to Alexza Pharmaceuticals, Inc., the developer of the Staccato inhalation platform and Adasuve. The issued patent is US 8,173,107 B2, titled “Aerosol formulations of loxapine” (U.S. Patent No. 8,173,107, 2012).

How are the claims structured?

Independent claims 1 and 5

Claims 1 and 5 are the two independent claims.

Claim 1 requires:

An aerosol;
Loxapine delivery by inhalation;
Condensation particles;
An MMAD from 0.2 to 5 microns; and
A high particle concentration.

Claim 5 replaces the less precise “high particle concentration” requirement with a numerical threshold: particle density greater than 10^6 particles/ml.

Claim 5 is therefore easier to assess quantitatively, but it may be broader in practical scope if “high particle concentration” in claim 1 is construed to mean a concentration substantially above the threshold in claim 5.

Dependent claims 2 through 4

Claim 2 requires the aerosol to be at least 90% free of additional compounds.

Claim 3 narrows the particle-size range to an MMAD of 1 to 3 microns.

Claim 4 narrows the concentration to about 10^9 particles/ml.

These claims are cumulative. A product accused under claim 4 would need to satisfy the limitations of claim 1 and have a concentration approximately around 10^9 particles/ml.

Dependent claims 6 through 8

Claims 6 through 8 repeat the narrowing features for claim 5:

Claim 6: at least 90% free of additional compounds;
Claim 7: MMAD of 1 to 3 microns;
Claim 8: particle density of about 10^9 particles/ml.

The duplicated claim sets create two infringement routes: one based on “high particle concentration” and another based on a numeric density greater than 10^6 particles/ml.

What is the technical scope of the condensation-particle limitation?

“Condensation particles” generally refers to particles formed by vaporization of loxapine followed by condensation into an aerosol particle. This differs from a conventional dry powder inhaler formulation in which micronized drug crystals are blended with a carrier or excipient.

The condensation-particle requirement is central. A competing product containing loxapine dissolved in a liquid nebulizer formulation, or loxapine powder dispersed in a carrier matrix, may avoid the claims if the resulting particles are not technically condensation particles.

The patent does not expressly require:

The Staccato inhaler;
A thermal vaporization device;
A specific dose of loxapine;
A particular loxapine salt;
A specific excipient;
A particular indication;
Treatment of agitation, schizophrenia, or bipolar disorder;
A particular emitted dose or delivery time.

A device-independent formulation claim can reach products using different inhaler hardware if the aerosol meets the claimed composition and particle characteristics.

What does MMAD mean in this patent?

MMAD means mass median aerodynamic diameter. It measures aerodynamic behavior, incorporating particle size, density, and shape. It is not simply the physical diameter measured by microscopy.

The claimed range of 0.2 to 5 microns is designed for pulmonary or deep-airway delivery. The preferred 1 to 3 micron range is narrower and more commercially important because it aligns with efficient respirable aerosol delivery.

A non-infringement analysis would need to examine:

The test method;
Sampling location;
Temperature and humidity;
Flow rate;
Whether the measurement is based on emitted aerosol or delivered aerosol;
Whether the particles change size after condensation;
Whether the result is a mass median or another particle-size metric.

A product with a geometric diameter within the range may still fall outside the claims if its MMAD is outside the claimed range. Conversely, particle density and morphology may cause an aerosol with a different geometric size to have an MMAD within the claim.

How important is the concentration limitation?

The concentration limitation is a major boundary on claim scope.

Claim 5 expressly requires particle density greater than 10^6 particles/ml. Claim 4 and claim 8 identify about 10^9 particles/ml as a preferred value. The patent therefore distinguishes a highly concentrated aerosol from a conventional dilute aerosol.

The concentration limitation may create significant proof issues because “particles/ml” depends on the measurement context. Relevant variables include:

Whether the volume is measured before or after inhalation;
Whether the aerosol is sampled inside the device or at the mouthpiece;
Whether agglomerates count as one particle or multiple particles;
Whether the measurement captures only drug-containing particles;
Whether the aerosol volume is calculated at standard temperature and pressure;
Whether the result is an instantaneous concentration or an average over the emitted dose.

The specification and prosecution history would be important in determining whether the concentration is measured in the aerosol plume, in the inhaler reservoir, or at another point in the delivery system.

What does “at least 90% free of additional compounds” cover?

Claims 2 and 6 require the aerosol to be at least 90% free of additional compounds. This limitation appears directed to a substantially neat loxapine aerosol rather than a formulation containing a large quantity of excipients, carriers, propellants, or other additives.

The principal claim-construction issue is the reference point for the 90% calculation. Possible interpretations include:

90% of the aerosol particle mass;
90% of the nonvolatile particle mass;
90% of the drug-containing composition;
90% by weight of the total formulation;
90% by number of particles.

The phrase “additional compounds” is broad. It could encompass excipients, stabilizers, carriers, surfactants, solvents, reaction products, or other chemical components, depending on the specification and prosecution record.

This limitation is not required by the independent claims. A product can potentially fall within claims 1 or 5 without satisfying claims 2 or 6.

What patent term applies to US 8,173,107?

The patent issued on May 8, 2012. Its priority chain traces to an application filed in December 2006, with the relevant nonprovisional or international filing period occurring in December 2007. On the ordinary 20-year patent-term calculation, the expected expiration is in December 2027, subject to any patent-term adjustment, terminal disclaimer, maintenance-fee event, or other statutory modification reflected in USPTO records.

Event	Date
Earliest priority period	December 2006
Approximate nonprovisional/PCT filing period	December 2007
Patent issued	May 8, 2012
Expected ordinary term end	December 2027

The patent’s enforceability must be checked against the current USPTO Patent Center record, including maintenance-fee status and any recorded term adjustment. Patent term is separate from FDA regulatory exclusivity.

What is the FDA regulatory status of loxapine inhalation?

Adasuve, containing loxapine, was approved by FDA on December 21, 2012. It is approved for the acute treatment of agitation associated with schizophrenia or bipolar disorder in adults. The product uses a single-use inhalation system based on rapid generation of a loxapine aerosol (FDA, 2012).

Adasuve is a small-molecule drug-device combination product. It is not a biologic, so biosimilar provisions under the Public Health Service Act do not apply. A competitor would generally pursue an abbreviated new drug application, a 505(b)(2) application, or another applicable pathway depending on the formulation, device, and reliance strategy.

FDA approval does not establish patent validity or infringement. It establishes regulatory authorization for the product and indication.

What is the Orange Book status of US 8,173,107?

A patent listed in the FDA Orange Book can delay approval of a qualifying generic product if the generic applicant files a Paragraph IV certification and the NDA holder or patent owner brings timely infringement litigation.

The commercial significance of US 8,173,107 depends on:

Whether it is listed against the relevant Adasuve strength and dosage form;
Whether the listing covers the approved product as opposed to an unapproved use;
Whether the patent is identified as a drug-substance, drug-product, or method-of-use patent;
Whether an ANDA applicant certifies Paragraph IV;
Whether a 30-month stay is triggered;
Whether the patent remains unexpired when the generic is otherwise approvable.

For an aerosol formulation patent, the listing is more likely to be relevant as a drug-product or formulation patent than as a pure method-of-use patent. FDA Orange Book entries and the current product patent table control the regulatory listing analysis (FDA, 2024).

When does loxapine inhalation lose exclusivity?

Adasuve’s FDA exclusivity and patent exclusivity are separate.

The product was approved in 2012. Any three-year exclusivity based on new clinical investigations would have operated from approval for the applicable conditions of approval. That regulatory exclusivity does not necessarily extend through the patent term.

The principal long-term barrier associated with US 8,173,107 is the expected patent term through December 2027. A generic or 505(b)(2) applicant could seek approval before that date if it can establish non-infringement, invalidity, unenforceability, or a permissible carve-out.

Exclusivity category	Relevance
New chemical entity exclusivity	Unlikely to apply because loxapine was previously approved
Three-year clinical-investigation exclusivity	Potentially relevant after the 2012 approval, subject to FDA designation
Orphan exclusivity	No basis is identified from the stated claims
Patent exclusivity	Expected to run into December 2027 absent earlier termination
Device exclusivity	Depends on the FDA product pathway and device-specific review

What Paragraph IV challenges and litigation affect this patent?

A Paragraph IV challenge would require a generic applicant to certify that the patent is invalid, unenforceable, or will not be infringed. The most likely theories against this patent would concern:

Whether the accused aerosol contains condensation particles;
Whether the MMAD falls within 0.2 to 5 microns;
Whether particle density exceeds 10^6 particles/ml;
Whether “high particle concentration” is indefinite;
Whether the claims are enabled across the full concentration and particle-size ranges;
Whether the claimed aerosol would have been obvious over earlier inhaled-drug aerosol technology;
Whether the patent properly claims priority to the earliest disclosure.

No biosimilar litigation applies because loxapine is a small molecule.

The patent’s claims do not depend on an approved method of use. A generic applicant cannot necessarily avoid them by omitting the agitation indication if the generic product itself contains the claimed aerosol. A method-of-use carve-out would be more useful against a use claim than against these composition claims.

How strong is the patent estate for Adasuve?

US 8,173,107 has meaningful but focused strength.

Strengths

It claims the aerosol composition directly.
It covers a broad MMAD range of 0.2 to 5 microns.
Claim 5 includes a measurable density threshold.
The claims do not require the branded device.
Claims 2 through 4 and 6 through 8 provide fallback positions.

Weaknesses

The claims depend on technically specialized measurements.
“Condensation particles” may require detailed product characterization.
“High particle concentration” may face indefiniteness or construction disputes.
The 0.2 to 5 micron range may be vulnerable to prior-art arguments involving respirable aerosols.
A competing product using a different loxapine particle-generation mechanism may avoid the claims.
The expected term ends in 2027, creating a finite remaining exclusivity period.

The patent is stronger against a copy of the Adasuve aerosol platform than against an unrelated loxapine inhalation technology.

What generic launch scenarios exist?

Scenario 1: Direct formulation copy

A generic using the same type of thermally generated loxapine condensation aerosol would face the highest infringement risk. If its product has an MMAD within 0.2 to 5 microns and density above 10^6 particles/ml, claim 5 would be a central barrier.

Scenario 2: Alternative aerosol-generation technology

A nebulized solution or conventional dry-powder product may avoid the condensation-particle limitation. It would still require FDA approval, device comparability or clinical support, and separate analysis of other Alexza or Adasuve-related patents.

Scenario 3: Particle-size design-around

A formulation engineered outside the claimed MMAD range could avoid literal infringement, but the product would need to retain adequate lung delivery and meet FDA performance requirements.

Scenario 4: Low-concentration formulation

A product with particle density at or below 10^6 particles/ml could avoid claim 5, although it may fail to reproduce the delivery performance of Adasuve.

Scenario 5: Post-expiration launch

A conventional generic launch after the patent term ends would remove this patent as a barrier, but other listed patents, device rights, regulatory exclusivity, manufacturing know-how, or supply constraints could remain relevant.

What manufacturing and intellectual-property barriers remain?

The patent claims provide only part of the commercial barrier. The Staccato platform may require proprietary manufacturing equipment, controlled thermal vaporization, aerosol plume control, dose uniformity processes, packaging, and device assembly know-how.

A competitor may need to solve:

Reproducible loxapine vaporization;
Particle nucleation and condensation;
Control of MMAD across batches;
High particle density without aggregation;
Dose uniformity;
Stability during storage;
Device activation and safety;
Human-factors requirements;
Combination-product manufacturing controls.

Trade secrets and unpatented process know-how can remain commercially important after patent expiration. They do not, however, independently establish patent infringement.

How does US 8,173,107 compare with ordinary loxapine formulations?

Product type	Likely relevance to US 8,173,107
Oral loxapine capsule	Outside the inhalation-aerosol limitations
Injectable loxapine	Outside the aerosol limitations
Conventional nebulized loxapine solution	May avoid the condensation-particle limitation
Dry-powder loxapine inhaler	Depends on whether particles are condensation particles
Staccato-generated loxapine aerosol	Highest potential overlap
Other inhaled loxapine aerosol	Requires MMAD and concentration analysis

Key Takeaways

US 8,173,107 is a formulation patent covering loxapine condensation aerosols.
Claims 1 and 5 are independent; claim 5 has the clearest quantitative threshold.
The core numerical limitations are MMAD of 0.2 to 5 microns and particle density greater than 10^6 particles/ml.
Preferred embodiments narrow the MMAD to 1 to 3 microns and density to about 10^9 particles/ml.
The patent does not require the Staccato device, a specific dose, or the approved agitation indication.
A conventional inhaled loxapine formulation may avoid infringement if it does not use condensation particles.
The expected ordinary patent term runs into December 2027, subject to the USPTO record.
Loxapine is a small molecule, so biosimilar litigation is irrelevant.
Generic risk is highest for a product that copies the Adasuve aerosol-generation mechanism and particle profile.
The principal legal vulnerabilities concern claim construction, enablement, obviousness, and proof of MMAD and particle density.

FAQs

Can a dry-powder loxapine inhaler infringe US 8,173,107?

Yes, if its particles qualify as condensation particles and satisfy the claimed MMAD and concentration limitations. A conventional crystalline dry powder would have a stronger non-infringement position.

Does the patent cover inhaled loxapine at every dose?

No. The claims do not recite a dose limitation, but they require the claimed aerosol particle characteristics and concentration.

Can a generic avoid the patent by omitting the schizophrenia indication?

Not necessarily. These are aerosol composition claims, not claims limited solely to treating schizophrenia. An indication carve-out would not by itself avoid infringement of a product that contains the claimed aerosol.

Is US 8,173,107 a device patent?

No. The claims provided are directed to an aerosol composition. The patent does not require a particular inhaler, although related device patents or trade secrets may affect commercialization.

What testing is most important in a Paragraph IV analysis?

The most important testing concerns particle-generation mechanism, MMAD, particle density, composition purity, and whether the aerosol contains additional compounds. The test protocol must match the claim-construction position and the product’s actual delivery state.

References

U.S. Patent No. 8,173,107. (2012). Aerosol formulations of loxapine. United States Patent and Trademark Office. https://patents.google.com/patent/US8173107B2/en
U.S. Food and Drug Administration. (2012). Adasuve approval letter. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/022549Orig1s000ltr.pdf
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
U.S. Food and Drug Administration. (2023). Adasuve prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/
United States Patent and Trademark Office. (2024). Patent term adjustment and patent term calculation guidance. https://www.uspto.gov/patents/laws/patent-term-adjustment-patent-term-extension-0
Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j). (2024). Abbreviated applications and certification procedures for listed patents. https://www.law.cornell.edu/uscode/text/21/355

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1389098	⤷ Start Trial	C300609	Netherlands	⤷ Start Trial
European Patent Office	1389098	⤷ Start Trial	CA 2013 00046	Denmark	⤷ Start Trial
European Patent Office	1389098	⤷ Start Trial	CR 2013 00046	Denmark	⤷ Start Trial
European Patent Office	1389098	⤷ Start Trial	1390040-2	Sweden	⤷ Start Trial
European Patent Office	1389098	⤷ Start Trial	300609	Netherlands	⤷ Start Trial
European Patent Office	1389098	⤷ Start Trial	473	Finland	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,173,107

Summary for Patent: 8,173,107